Braveheart Bio (BRVE) vs Septerna (SEPN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Braveheart Bio is the larger company by market cap ($1.63 billion vs $1.63 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BRVE | SEPN |
|---|---|---|
| Share price | $18.08 | $34.87 |
| Market cap | $1.63B | $1.63B |
| 1-day change | -2.69% | -3.15% |
| YTD return | — | +29.12% |
| 1-year return | — | +71.35% |
| EPS (TTM) | $-6.08 | $-0.54 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $32.00 | $51.10 |
| 52-week low | $17.91 | $17.55 |
| Distance from 52-week high | -43.50% | -31.77% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +150.28% | +55.51% |
| Average volume | 562.23K | 393.97K |
| Shares outstanding | 90.04M | 46.68M |
| Employees | 49 | 123 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Braveheart Bio
BRVE stock →Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees
About Septerna
SEPN stock →Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 123 employees
BRVE vs SEPN FAQ
Which is bigger, Braveheart Bio or Septerna?
Braveheart Bio (BRVE) is larger, with a market capitalization of $1.63B compared with $1.63B for Septerna (SEPN).
Are Braveheart Bio and Septerna in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.